Smartlab Europe

News

GSK to support manufacture of Novavax COVID-19 vaccine

GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax’ COVID-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide ‘fill...

EMA issues advice on the use of Celltrion’s anti-COVID-19 monoclonal antibody treatment regdanvimab for COVID-19 patients in the EU

Celltrion Group announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for the company’s anti-COVID-19 monoclonal antibody treatment candidate, regdanvimab (CT-P59). The CHMP recommends that regdanvimab can be...

University team uses AI to decode asbestos-linked cancer

Researchers at the University of Leicester have used artificial intelligence (AI) to gain new insights into mesothelioma, a cancer caused by breathing asbestos particles that typically occurs in the linings of the lungs or abdomen. The Leicester Mesothelioma Research Programme...

Key milestone in molded glass: SGD Pharma elevates Type I offering with three tailored product and service solutions

SGD Pharma, a leading supplier of glass primary packaging in the pharmaceutical industry and global expert in Type I molded glass, introduces an industry first offering of Type I molded glass vials. These market-driven value propositions represent the latest...

CyanVac Selects Exothera for the Development and GMP Mfg anufacturing of its COVID-19 Intranasal Vaccine Candidate for Phase III Clinical Trial is Europe and...

CyanVac LLC, a vaccine company, announced that they have selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO), for the development and manufacturing of their COVID-19 intranasal vaccine based on a proprietary parainfluenza virus 5 (PIV5) vector. Exothera...

Stelis concludes US$ 195m Series B and Series C fund raise

Stelis Biopharma (Stelis) announced that it has successfully concluded its Series B and Series C fund raise for a cumulative amount of US$ 195m. Post money valuation for Stelis will be pegged at ~US$ 350m, underpinning the significant growth...

Peli BioThermal Broadens Portfolio of Dry Ice Shippers

Peli BioThermal, the global name in temperature controlled packaging, announces expanded dry ice shipper options to support exponential growth in cell and gene therapy shipments worldwide, as well as continued need to transport pandemic payloads. Available parcel sizes range...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »